Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab (KIA-ProRet)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00776763 |
Recruitment Status :
Completed
First Posted : October 21, 2008
Last Update Posted : July 22, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Aims of the trial: Establishing the profile of the growth factors and other mediators of angiogenesis in different ocular fluids (aqueous humour, vitreous gel and ocular liquid in vitrectomized eyes), in the 2 most frequent proliferative retinopathies - diabetic proliferative retinopathy (PDR) and exudative age related macular degeneration (AMD). Following up the dynamic of this profile before and after intravitreal administration of Bevacizumab (Avastin) as an anti-VEGF blocker.
Materials: The research will be conducted on the following categories of patients groups:
- nondiabetic patients without AMD or any other diagnosed proliferative ocular disease (controls)
- patients with age related macular degeneration (AMD groups) before and after intravitreal injections with Avastin
- diabetic patients with different types of diabetic retinopathy, before and after intravitreal Avastin (diabetic groups) Methods: Samples from different ocular fluids will be collected from each group of patients. 10 growth factors and other 10 cytokines will be determined in the ocular fluids samples.
Results: The results from the biochemical measurements will be statistically interpreted in order to obtain conclusions for the clinical practice.
Conclusions: The conclusions of this trial will be used exclusively for research publications and communications, as well as for clinical practice.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Proliferative Diabetic Retinopathy Age Related Macular Degeneration | Drug: Avastin intravitreal injection | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 150 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | The Profile of the Growth Factors and Other Mediators of Angiogenesis in the Ocular Fluids in Proliferative Retinopathies (AMD and PDR) Before and After the Intravitreal Administration of Bevacizumab (Avastin) as an Anti-VEGF Blocker |
Study Start Date : | October 2008 |
Actual Primary Completion Date : | October 2009 |
Actual Study Completion Date : | December 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: Avastin |
Drug: Avastin intravitreal injection
1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy) |
- Growth Factors and Other Cytokines Measurements [ Time Frame: 1 month interval ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age over 20 years
- nondiabetic patients requiring cataract surgery or vitrectomy for different posterior segment nonproliferative disorders - controls groups
- diabetic patients asking ophthalmologic treatments for different degrees of decreasing of visual acuity - diabetic groups
- diabetic patients requiring cataract surgery or vitrectomy - diabetic groups
- age related macular degeneration patients asking ophthalmologic treatments for different degrees of decreasing of visual acuity - age related macular degeneration groups
- age related macular degeneration patients requiring cataract surgery or vitrectomy - age related macular degeneration groups
Exclusion Criteria:
- patients under the age of 20 years
- patients that did not accept and signed the informed consent of the trial
- patients that received any anti-VEGF therapy for any proliferative or inflammatory ocular disease
- patients that received any type of intraocular injection with any pharmaceutical agent
- patients with any clinical type of malignancy in their pathologic antecedents
- patients with recent penetrating trauma (less than 1 year old)
- patients operated for different ocular disorders requiring combination with antimetabolites (ex. 5-FU or Mitomycin C with trabeculectomy)
- patients with intraocular inflammations or infections or other pathologies that contraindicate open globe surgery or intraocular injections with anti-VEGF blockers

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00776763
Romania | |
Railway Universitary Hospital | |
Iasi, Romania, 700506 |
Principal Investigator: | NARCISA IANOPOL, Researcher | Railway Universitary Hospital |
Responsible Party: | NARCISA IANOPOL, Md, PhD, Railway Universitary Hospital |
ClinicalTrials.gov Identifier: | NCT00776763 |
Other Study ID Numbers: |
KIA-ProRet |
First Posted: | October 21, 2008 Key Record Dates |
Last Update Posted: | July 22, 2011 |
Last Verified: | October 2008 |
Macular Degeneration Retinal Diseases Diabetic Retinopathy Retinal Degeneration Eye Diseases Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Diabetes Complications Diabetes Mellitus |
Endocrine System Diseases Bevacizumab Antineoplastic Agents, Immunological Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors |